Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Transcutaneous spinal direct current stimulation improves locomotor learning in healthy humans.

Awosika OO, Sandrini M, Volochayev R, Thompson RM, Fishman N, Wu T, Floeter MK, Hallett M, Cohen LG.

Brain Stimul. 2019 May - Jun;12(3):628-634. doi: 10.1016/j.brs.2019.01.017. Epub 2019 Jan 29.

PMID:
30733143
2.

Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in C9orf72.

Floeter MK, Gendron TF.

Front Neurol. 2018 Dec 5;9:1063. doi: 10.3389/fneur.2018.01063. eCollection 2018. Review.

3.

Loss of functional connectivity is an early imaging marker in primary lateral sclerosis.

Clark MG, Smallwood Shoukry R, Huang CJ, Danielian LE, Bageac D, Floeter MK.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):562-569. doi: 10.1080/21678421.2018.1517180. Epub 2018 Oct 9.

PMID:
30299161
4.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

5.

Longitudinal diffusion imaging across the C9orf72 clinical spectrum.

Floeter MK, Danielian LE, Braun LE, Wu T.

J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):53-60. doi: 10.1136/jnnp-2017-316799. Epub 2017 Oct 20.

6.

Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis.

Gendron TF; C9ORF72 Neurofilament Study Group, Daughrity LM, Heckman MG, Diehl NN, Wuu J, Miller TM, Pastor P, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Benatar M, Silani V, Glass JD, Floeter MK, Jeromin A, Boylan KB, Petrucelli L.

Ann Neurol. 2017 Jul;82(1):139-146. doi: 10.1002/ana.24980.

7.

Disease progression in C9orf72 mutation carriers.

Floeter MK, Traynor BJ, Farren J, Braun LE, Tierney M, Wiggs EA, Wu T.

Neurology. 2017 Jul 18;89(3):234-241. doi: 10.1212/WNL.0000000000004115. Epub 2017 Jun 14.

8.
9.

Pathology of callosal damage in ALS: An ex-vivo, 7 T diffusion tensor MRI study.

Cardenas AM, Sarlls JE, Kwan JY, Bageac D, Gala ZS, Danielian LE, Ray-Chaudhury A, Wang HW, Miller KL, Foxley S, Jbabdi S, Welsh RC, Floeter MK.

Neuroimage Clin. 2017 Apr 30;15:200-208. doi: 10.1016/j.nicl.2017.04.024. eCollection 2017.

10.

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O'Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, Van Swieten JC, Miller BL, Boxer AL, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L.

Sci Transl Med. 2017 Mar 29;9(383). pii: eaai7866. doi: 10.1126/scitranslmed.aai7866.

11.

Longitudinal imaging in C9orf72 mutation carriers: Relationship to phenotype.

Floeter MK, Bageac D, Danielian LE, Braun LE, Traynor BJ, Kwan JY.

Neuroimage Clin. 2016 Oct 22;12:1035-1043. eCollection 2016.

12.

Phenotypic and molecular analyses of primary lateral sclerosis.

Mitsumoto H, Nagy PL, Gennings C, Murphy J, Andrews H, Goetz R, Floeter MK, Hupf J, Singleton J, Barohn RJ, Nations S, Shoesmith C, Kasarskis E, Factor-Litvak P.

Neurol Genet. 2015 Apr 14;1(1):e3. doi: 10.1212/01.NXG.0000464294.88607.dd. eCollection 2015 Jun.

13.

Cortical hyperexcitability in patients with C9ORF72 mutations: Relationship to phenotype.

Schanz O, Bageac D, Braun L, Traynor BJ, Lehky TJ, Floeter MK.

Muscle Nerve. 2016 Aug;54(2):264-9. doi: 10.1002/mus.25047. Epub 2016 May 25.

14.

Primary Lateral Sclerosis.

Statland JM, Barohn RJ, Dimachkie MM, Floeter MK, Mitsumoto H.

Neurol Clin. 2015 Nov;33(4):749-60. doi: 10.1016/j.ncl.2015.07.007. Epub 2015 Sep 8. Review.

15.

Cerebro-cerebellar connectivity is increased in primary lateral sclerosis.

Meoded A, Morrissette AE, Katipally R, Schanz O, Gotts SJ, Floeter MK.

Neuroimage Clin. 2014 Dec 9;7:288-96. doi: 10.1016/j.nicl.2014.12.009. eCollection 2015.

16.

Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS.

Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P, Johnston A, Overstreet K, Oh SY, Todd PK, Berry JD, Cudkowicz ME, Boeve BF, Dickson D, Floeter MK, Traynor BJ, Morelli C, Ratti A, Silani V, Rademakers R, Brown RH, Rothstein JD, Boylan KB, Petrucelli L, Disney MD.

Neuron. 2014 Oct 1;84(1):239. doi: 10.1016/j.neuron.2014.09.019. Epub 2014 Oct 1. No abstract available.

17.

Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS.

Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P, Johnston A, Overstreet K, Oh SY, Todd PK, Berry JD, Cudkowicz ME, Boeve BF, Dickson D, Floeter MK, Traynor BJ, Morelli C, Ratti A, Silani V, Rademakers R, Brown RH, Rothstein JD, Boylan KB, Petrucelli L, Disney MD.

Neuron. 2014 Sep 3;83(5):1043-50. doi: 10.1016/j.neuron.2014.07.041. Epub 2014 Aug 14. Erratum in: Neuron. 2014 Oct 1;84(1):239.

18.

Impaired corticopontocerebellar tracts underlie pseudobulbar affect in motor neuron disorders.

Floeter MK, Katipally R, Kim MP, Schanz O, Stephen M, Danielian L, Wu T, Huey ED, Meoded A.

Neurology. 2014 Aug 12;83(7):620-7. doi: 10.1212/WNL.0000000000000693. Epub 2014 Jul 9.

19.

Disease spread through contiguity and axonal tracts in primary lateral sclerosis.

Flynn L, Stephen M, Floeter MK.

Muscle Nerve. 2014 Mar;49(3):439-41. doi: 10.1002/mus.24116. Epub 2014 Jan 27.

20.

Imaging findings associated with cognitive performance in primary lateral sclerosis and amyotrophic lateral sclerosis.

Meoded A, Kwan JY, Peters TL, Huey ED, Danielian LE, Wiggs E, Morrissette A, Wu T, Russell JW, Bayat E, Grafman J, Floeter MK.

Dement Geriatr Cogn Dis Extra. 2013 Aug 16;3(1):233-50. doi: 10.1159/000353456. eCollection 2013.

21.

Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis.

Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, Floeter MK, Henderson C, Lomen-Hoerth C, Macklis JD, McCluskey L, Mitsumoto H, Przedborski S, Rothstein J, Trojanowski JQ, van den Berg LH, Ringel S.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:5-18. doi: 10.3109/21678421.2013.778548.

22.

Effects of motor skill learning on reciprocal inhibition.

Floeter MK, Danielian LE, Kim YK.

Restor Neurol Neurosci. 2013;31(1):53-62. doi: 10.3233/RNN-120247.

23.

Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology.

Kwan JY, Jeong SY, Van Gelderen P, Deng HX, Quezado MM, Danielian LE, Butman JA, Chen L, Bayat E, Russell J, Siddique T, Duyn JH, Rouault TA, Floeter MK.

PLoS One. 2012;7(4):e35241. doi: 10.1371/journal.pone.0035241. Epub 2012 Apr 17.

24.

Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Rakocevic G, Floeter MK.

Muscle Nerve. 2012 May;45(5):623-34. doi: 10.1002/mus.23234. Review.

25.

Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis.

Kwan JY, Meoded A, Danielian LE, Wu T, Floeter MK.

Neuroimage Clin. 2012 Dec 24;2:151-60. doi: 10.1016/j.nicl.2012.12.003. eCollection 2012.

26.

White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis.

Iwata NK, Kwan JY, Danielian LE, Butman JA, Tovar-Moll F, Bayat E, Floeter MK.

Brain. 2011 Sep;134(Pt 9):2642-55. doi: 10.1093/brain/awr178. Epub 2011 Jul 28.

27.

Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.

Lehky TJ, Iwamoto FM, Kreisl TN, Floeter MK, Fine HA.

Neurology. 2011 Jan 18;76(3):236-41. doi: 10.1212/WNL.0b013e3182074a69.

28.

Towards a user-friendly brain-computer interface: initial tests in ALS and PLS patients.

Bai O, Lin P, Huang D, Fei DY, Floeter MK.

Clin Neurophysiol. 2010 Aug;121(8):1293-303. doi: 10.1016/j.clinph.2010.02.157. Epub 2010 Mar 29.

29.

A pilot study of the prevalence of psychiatric disorders in PLS and ALS.

Huey ED, Koppel J, Armstrong N, Grafman J, Floeter MK.

Amyotroph Lateral Scler. 2010 May 3;11(3):293-7. doi: 10.3109/17482960903544576.

30.

Progression in primary lateral sclerosis: a prospective analysis.

Floeter MK, Mills R.

Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):339-46. doi: 10.3109/17482960903171136.

31.

Reliability of fiber tracking measurements in diffusion tensor imaging for longitudinal study.

Danielian LE, Iwata NK, Thomasson DM, Floeter MK.

Neuroimage. 2010 Jan 15;49(2):1572-80. doi: 10.1016/j.neuroimage.2009.08.062. Epub 2009 Sep 8.

32.

Standard and modified statistical MUNE evaluations in spinal-bulbar muscular atrophy.

Lehky TJ, Chen CJ, di Prospero NA, Rhodes LE, Fischbeck K, Floeter MK.

Muscle Nerve. 2009 Nov;40(5):809-14. doi: 10.1002/mus.21399.

33.

Recommendations of the Neurolaryngology Study Group on laryngeal electromyography.

Blitzer A, Crumley RL, Dailey SH, Ford CN, Floeter MK, Hillel AD, Hoffmann HT, Ludlow CL, Merati A, Munin MC, Robinson LR, Rosen C, Saxon KG, Sulica L, Thibeault SL, Titze I, Woo P, Woodson GE.

Otolaryngol Head Neck Surg. 2009 Jun;140(6):782-793. doi: 10.1016/j.otohns.2009.01.026. Epub 2009 Apr 9. Review.

34.

Usage of support services in primary lateral sclerosis.

Peters TL, Floeter MK.

Amyotroph Lateral Scler. 2009 Jun;10(3):187-91. doi: 10.1080/17482960902818224.

35.

A high performance sensorimotor beta rhythm-based brain-computer interface associated with human natural motor behavior.

Bai O, Lin P, Vorbach S, Floeter MK, Hattori N, Hallett M.

J Neural Eng. 2008 Mar;5(1):24-35. doi: 10.1088/1741-2560/5/1/003. Epub 2007 Dec 11.

PMID:
18310808
36.

Physiology of the motor cortex in polio survivors.

Lupu VD, Danielian L, Johnsen JA, Vasconcelos OM, Prokhorenko OA, Jabbari B, Campbell WW, Floeter MK.

Muscle Nerve. 2008 Feb;37(2):177-82.

PMID:
17990291
37.

Decreased thickness of primary motor cortex in primary lateral sclerosis.

Butman JA, Floeter MK.

AJNR Am J Neuroradiol. 2007 Jan;28(1):87-91.

38.

Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins.

Lupu VD, Mora CA, Dambrosia J, Meer J, Dalakas M, Floeter MK.

Muscle Nerve. 2007 Feb;35(2):196-202.

PMID:
17068765
39.

Movement-related cortical potentials in primary lateral sclerosis.

Bai O, Vorbach S, Hallett M, Floeter MK.

Ann Neurol. 2006 Apr;59(4):682-90.

PMID:
16566016
40.

Distal spinal and bulbar muscular atrophy caused by dynactin mutation.

Puls I, Oh SJ, Sumner CJ, Wallace KE, Floeter MK, Mann EA, Kennedy WR, Wendelschafer-Crabb G, Vortmeyer A, Powers R, Finnegan K, Holzbaur EL, Fischbeck KH, Ludlow CL.

Ann Neurol. 2005 May;57(5):687-94.

41.

Motor neuron firing dysfunction in spastic patients with primary lateral sclerosis.

Floeter MK, Zhai P, Saigal R, Kim Y, Statland J.

J Neurophysiol. 2005 Aug;94(2):919-27. Epub 2005 Apr 13.

42.

WITHDRAWN: Second AAEM literature review of the usefulness of nerve conduction studies and needle electromyography for the evaluation of patients with carpal tunnel syndrome.

Jablecki CK, Andary MT, Floeter MK, Miller RG, Quartly CA, Vennix MJ, Wilson JR.

Muscle Nerve. 2002 Jun 11. [Epub ahead of print]

PMID:
15389664
43.

Do F-wave measurements detect changes in motor neuron excitability?

Lin JZ, Floeter MK.

Muscle Nerve. 2004 Sep;30(3):289-94.

PMID:
15318339
44.

Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.

Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK.

Muscle Nerve. 2004 Mar;29(3):387-92.

PMID:
14981738
45.

Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.

Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO.

Muscle Nerve. 2003 Dec;28(6):703-10.

PMID:
14639584
46.

Cutaneous silent periods.

Floeter MK.

Muscle Nerve. 2003 Oct;28(4):391-401. Review.

PMID:
14506711
47.

Primary lateral sclerosis: A heterogeneous disorder composed of different subtypes?

Zhai P, Pagan F, Statland J, Butman JA, Floeter MK.

Neurology. 2003 Apr 22;60(8):1258-65.

PMID:
12707427
48.

Patterned sensory stimulation induces plasticity in reciprocal ia inhibition in humans.

Perez MA, Field-Fote EC, Floeter MK.

J Neurosci. 2003 Mar 15;23(6):2014-8.

49.

Mutant dynactin in motor neuron disease.

Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH.

Nat Genet. 2003 Apr;33(4):455-6. Epub 2003 Mar 10.

PMID:
12627231
50.

Increased brainstem excitability in stiff-person syndrome.

Molloy FM, Dalakas MC, Floeter MK.

Neurology. 2002 Aug 13;59(3):449-51.

PMID:
12177385

Supplemental Content

Loading ...
Support Center